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Mycobacterium tuberculosis complex (MTBC) members are causative agents of human and animal tuberculosis.
Differentiation of MTBC members is required for appropriate treatment of individual patients and for epidemiologi-
cal purposes. Strains from six MTBC species – M. tuberculosis, M. bovis subsp. bovis, M. bovis BCG, M. africanum,
M. pinnipedii, and “M. canetti” – were studied using gyrB-restriction fragment length polymorphism (gyrB-RFLP)
analysis. A table was elaborated, based on observed restriction patterns and published gyrB sequences. To evaluate
applicability of gyrB-RFLP at Instituto Adolfo Lutz, São Paulo, Mycobacterial Reference Laboratory, 311 MTBC
clinical isolates, previously identified using traditional methods as M. tuberculosis (306), M. bovis (3), and M.
bovis BCG (2), were analyzed by gyrB-RFLP. All isolates were correctly identified by the molecular method, but no
distinction between M. bovis and M. bovis BCG was obtained. Differentiation of  M. tuberculosis and M. bovis is of
utmost importance, because they require different treatment schedules. In conclusion, gyrB-RFLP is accurate and
easy-to-perform, with potential to reduce time needed for conventional differentiation methods. However, applica-
tion for epidemiological studies remains limited, because it cannot differentiate M. tuberculosis from M. africanum
subtype II, and “M. canetti”, M. africanum subtype I from M. pinnipedii, and. M. bovis from M. bovis BCG.
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Tuberculosis is one of the leading causes of death
due to infectious agents. Ninety-five per cent of cases
occur in the developing world, where few resources are
available for diagnostic and treatment (ATS 2000). Mem-
bers of Mycobacterium tuberculosis complex (MTBC) are
the causative agents of tuberculosis in humans and ani-
mals and, despite genetic close relationship, they differ in
epidemiology, pathogenicity, geographic range, host pref-
erence, and in importance for tuberculosis disease in hu-
mans. MTBC includes M. tuberculosis, M. bovis subsp.
bovis, M. bovis subsp. caprae, M. bovis BCG vaccine
strain, M. africanum (subtypes I and II), M. microti, and
“M. canetti”. The last member of this list has still not
been officially recognized on the list of Bacterial Names
with Standing in Nomenclature [http://www.bacterio.
cict.fr].  A novel member, M. pinnipedii, proposed by
Cousins et al. (2003), has been well-characterized as a
specie of M. tuberculosis complex. Genetically, all mem-
bers of this complex are extremely similar, having 99.9%
similarity at the nucleotide level and identical 16SrRNA
sequences (Brosch et al. 2002).
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Early diagnosis is essential for tuberculosis control.
The high degree of sequence conservation among mem-
bers of MTBC makes differentiation of species in the clini-
cal mycobacteriology laboratory a difficult task. Routine
differentiation is still based on phenotypic characteris-
tics, such as oxygen preference, niacin accumulation, ni-
trate reductase activity, colony morphology, and resis-
tance to two compounds, 2-thiophen-carboxylic acid hy-
drazide (TCH) and pyrazinamide (PZA) (Collins et al. 1997).
These tests need sufficient bacterial growth, are time-con-
suming and are not performed by many laboratories rou-
tinely. Species belonging to MTBC cannot be differenti-
ated by small subunit rRNA (16SrRNA) or internal tran-
scribed spacer (ITS) sequencing. Molecular techniques
were designed to rapidly differentiate MTBC species, as
Spoligotyping (Kamerbeek et al. 1997), methods to detect
mutations in pncA and oxyR genes (Scorpio et al. 1996,
Sreevatsan et al. 1996), mtp40-PCR (Del Portillo et al. 1991,
Liébana et al. 1996), and PCR-amplification of regions of
difference (RD) (Parsons et al. 2002, Huard et al. 2003),
among others. There are some limitations for the use of
these techniques.  pncA, oxyR, and mtp40 are useful for
differentiation of M. tuberculosis and M. bovis, but not
for other MTBC members. Spoligotyping requires analy-
sis of several isolates in the same experiment and RD analy-
sis requires several amplification steps.
The gyrB gene encodes the B subunit of DNA gyrase
(topoisomerase II), an enzyme universally distributed and
essential for bacterial replication. Kasai et al. (2000) ob-
tained gyrB nucleotide sequences from different strains
of M. tuberculosis, M. bovis, M. africanum, and M. mi-
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croti. A two-step method for differentiation of these spe-
cies was developed, based on gyrB. In the first step, a
1020 bp fragment of the gene is amplified with specific
primers, which do not generate amplicons from other spe-
cies of mycobacteria. In the second step, the amplicon is
digested with restriction enzymes. Analysis of restriction
fragment length polymorphisms (RFLP) allows distinction
of M. tuberculosis, M. bovis, M. africanum, and M. microti.
Niemann et al. (2000) extended these observations and
proposed a diagnostic algorithm of gyrB-RFLP patterns
to differentiate M. tuberculosis/M. africanum II from M.
africanum I, M. bovis subsp. bovis, M. bovis subsp.
caprae and M. microti.
In order to implement gyrB-RFLP in the Reference
Laboratory at Instituto Adolfo Lutz, in São Paulo, Brazil,
we analyzed gyrB-RFLP patterns from reference strains,
including M. tuberculosis H37Rv (ATCC 27294), M. bovis
(AN5), and M. bovis BCG (Pasteur), “M. canetti” isolate
140010059 and M. africanum isolate 140010068 from the
National Reference Laboratory for Mycobacteria at
Institut Pasteur (Paris, France) culture collection, kindly
provided by Dr Véronique Vincent, and M. pinnipedii iso-
late 1458, kindly provided by Amelia Bernardelli  (Senasa,
Buenos Aires, Argentina). Amplifications were performed
using purified DNA or bacteria lysed by freezing and thaw-
ing, using the protocol described by Kasai et al. (2000),
with modifications. Mycobacteria DNA was added to PCR
mix containing 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5
mM MgCl2, 1U of Taq DNA polymerase (Invitrogen), 0.2
mM of each deoxynucleoside triphosphate, and 100 pmol
of each primer MTUBf (5’TCGGACGCGTATGCGATATC)
and MTUBr (5’ACATACAGTTCGGACTTGCG). After ini-
tial denaturation for 10 min at 95ºC, 35 amplification cycles
were completed, each consisting of 1 min at 94ºC, 1 min at
65ºC and 1,5 min at 72ºC. A final extension of 10 min at
72ºC was applied. The amplification product was analyzed
by restriction with RsaI, TaqI and SacII. Restriction di-
gests were separated in 2% agarose gels together with 50
bp DNA ladder (Invitrogen), applied in a separate lane.
Gels were stained with ethidium bromide and photo-
graphed on UV transiluminator. RFLPs in the 1020-bp gyrB
fragments were analyzed using GelCompar II v. 2.5 pro-
gram (AppliedMaths, Sint-Martens-Latem, Belgium) (Fig.
1).
After analysis of the results we observed that some
bands showed different sizes from those described by
Niemann et al. (2000). Also, small bands, not considered
by Kasai et al. (2000) and Niemann et al. (2000), were clearly
visible and helped in species differentiation (Fig. 1). Thus,
we developed a new table based on band sizes calculated
using GelCompar and confirmed by analysis of sequences
deposited by Kasai et al. (2000) in DNA DataBank of Ja-
pan  (http://www.mbio.co.jp/icb/icb.html) (Fig. 2). This new
table describes for the first time the gyrB-RFLP patterns
of “M. canetti”, indistinguishable from M. tuberculosis,
and of M. pinnipedii, indistinguishable from M. africanum
I. This last result confirms findings described by Cousins
et al. (2003), demonstrating that seal isolates were geneti-
cally closer to M. tuberculosis and M. africanum than to
M. bovis.
To evaluate the clinical applicability of gyrB-RFLP, we
analyzed 311 MTBC isolates cultured from patients living
in different cities of the state of São Paulo. A set of 307
clinical MTBC isolates, were consecutively received at
the Mycobacteriology Laboratory at Instituto Adolfo Lutz
(IAL) for susceptibility and identification tests from Jan 9
2003 to Mar 7 2003. From these isolates, 83 (27.1%) came
from cities of the state of São Paulo and 224 (72.9%) from
the Metropolitan Region of Great São Paulo. They were
cultured from sputum (268 samples), bronchial washes
(8), lymph nodes (9), pleural fluids (4), urine (4), blood (4),
cerebrospinal fluids (4), gastric washes (3), abscesses from
unknown sites (2), and skin biopsy (1). For differentiation
of MTBC, isolates were examined using biochemical and
drug susceptibility tests. Biochemical tests include ni-
trate reduction, niacin accumulation test (BBL Taxo TB
niacin test, Becton Dickinson, US) and growth in the pres-
ence of TCH (5 µg/ml), p-nitrobenzoic acid (PNB) (0.5 mg/
ml) and cycloserine (0.02 mg/ml). Drug susceptibility was
determined by the resistance ratio method in Löwenstein
Fig. 1: gyrB patterns analyzed using GelCompar II. Lanes 1: Mycobacterium bovis BCG; 2: M. bovis subsp. bovis; 3: M. pinnipedii; 4: M.
africanum; 5: “M. canetti”; 6: M. tuberculosis
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Jensen (LJ) medium containing isoniazid (INH), rifampi-
cin (RF), ethambutol (EMB) and streptomycin (SM)
(Collins et al. 1997). Pyrazinamide (PZA) susceptibility
was tested by detection of pyrazinamidase activity (Collins
et al. 1997). At Instituto Adolfo Lutz, drug susceptibility
test is performed under specific criteria. All isolates cul-
tured from cases of HIV positive, multidrug resistance
tuberculosis, relapses, default and treatment failure are
tested to INH, RF, and PZA. If some resistance occurs,
the isolates are further tested to EMB and SM. Isolates
not matching any of these criteria were investigated ex-
clusively by biochemical tests. According to the IAL crite-
ria, 198 isolates were subjected to susceptibility tests and
109 isolates to biochemical tests for identification. Out of
307 isolates, 306 (99.7%) were identified as M. tuberculo-
sis and one as M. bovis BCG. Two clinical isolates of M.
bovis and two of M. bovis BCG belonging to IAL strain
collection were also included for analysis of gyrB pat-
terns.
gyrB-RFLP revealed 306 isolates with the profile com-
mon to M. tuberculosis, M. africanum II, and “M. canetti”
and five with the pattern common to M. bovis subsp. bovis
and M. bovis BCG. Lack of restriction with SacII excluded
the presence of M. bovis subsp. caprae (data not shown).
Despite evidences that the prevalence of M. africanum
II and “M. canetti” in non-African populations is ex-
tremely low, data presented here cannot confirm that these
species are not present among the analyzed isolates, first
because M. tuberculosis, “M. canetti”, and M. africanum
subtype II are indistinguishable by gyrB-RFLP, and sec-
ond because this study was not specifically designed to
verify this point. M. bovis and M. bovis BCG were also
not differentiated by gyrB-RFLP. Both are sensitive to the
usual antituberculosis drugs, isoniazid and rifampin, but
resistant to pyrazinamide. Therefore, from the point of
view of treatment, simple differentiation of M. tuberculo-
sis from M. bovis, achieved by gyrB-RFLP, is satisfactory.
No association between gyrB genotype and drug re-
sistance was found, as expected. Among 198 isolates sub-
jected to susceptibility tests, 165 (83.3%) were sensitive
to INH, RF, PZA, and 33 (16.7%) were resistant at least to
one drug (data not shown). All 198 isolates presented
indistinguishable gyrB-RFLP pattern common to M. tu-
berculosis, “M. canetti”, and M. africanum II.
In conclusion, gyrB-RFLP can differentiate MTBC
species with easy-to perform PCR, enzymatic restriction
and gel electrophoresis. Consequently, it holds many ad-
vantages for the clinical laboratory, in terms of improve-
ment in accuracy and savings in time and cost. It has the
potential to reduce time required for identification when
compared to conventional methods. The test can be sim-
plified by the use of only two enzymes, RsaI and TaqI,
which are sufficiently discriminatory. The third enzyme,
SacII could be reserved for situations in which differen-
tiation of M. bovis subsp. bovis and M. bovis subsp.
caprae may be required.
Application of gyrB-RFLP for epidemiological studies
remains limited, because it cannot differentiate M. tuber-
culosis from M. africanum subtype II and “M canetti”,
M. africanum subtype I from M. pinnipedii, and M. bovis
from M. bovis BCG. For this purpose, other strategies have
to be pursued.
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